Welcome to BOLT International

Latest News (May 7 2014)

Cancer Immunotherapy; Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma is the 38th hematology/oncology Thought Leader Panel published by BOLT International.  We conducted in-depth interviews with ten peer recognized experts in the treatment of these three diseases.  We asked them to summarize the successes and challenges in establishing immunotherapy as a co-pillar of modern cancer treatment along with chemotherapy and targeted therapy.  And while other solid tumors can already be added to the list, the thought leaders focused on these three as they evaluated checkpoint inhibitors (certainly too narrow of a description), tumor infiltrating lymphocytes, biological response modifiers, vaccines and chimeric antigen receptors.  This report captures their collective wisdom.

As with all of our reports, we (reasonably) expect that Pharma foots the bill, but if you are a patient with one of these diseases, we will gladly share WITH YOUR PHYSICIAN (he must directly contact us and ask) relevant excerpts.

 

 

Keywords in this report: checkpoint, ipilimumab, Yervoy, MK-3475, Merck, nivolumab, BMS-936558 , Bristol-Myers Squibb, BMS, BRAF, MEK, Pegasys, interferon, aldesleukin, Prometheus, Avastin, bevacizumab, sunitinib, Votrient, pazopanib, GlaxoSmithKline, Inlyta, axitinib, Afinitor, everolimus, Novartis, MPDL3280A, Roche, Genentech, tremelimumab, AstraZeneca, MedImmune, MSB0010718C, EMD Serono, MEDI0680, MEDI4736, BiocerOX, pidilizumab, CT-011, CureTech, Teva, ANB011, AnaptysBio, OX40, Medimmune, BMS663513, urelumab, 41-BB, CD137, PF-05082566, PF-2566, Pfizer, TRX-518, GITR, VISTA, B7-H5, Gi24, Dies1, Janssen, ImmuNext, B7-H3, CD276, MGA-271, Servier, Macrogenics, LAG-3, lymphocyte-activation gene 3, CD223, BMS-986016, IMP321, IMP701, Immutep, TIM-3,T cell immunoglobulin and mucin domain 3, Brigham & Women’s, IDO, Indoleamine 2, 3-dioxygenase, INCB24360, Incyte, indoximod, NewLink, NLG919, NewLink, KIR, lirilumab, MICA, IPH4102, Innate Pharma, PS, phosphatidyl serine, bavituximab, Peregrine, TIL, tumor Infiltrating lymphocytes, adoptive T-cell transfer, biological response modifiers, IL-2, Pegasys, Roche, Proleukin, High Dose IL2, Prometheus, IL12, Ad-RTS-hIL-12, Ziopharm, T-cell Vaccines, talimogene laherparepvec, T-VEC,  Amgen, AGS-003, Argos, Tumor Associated Peptide Vaccines, IMA901, Immatics Biotechnologies GmbH, CAR, Carbonic Anhydrase IX CAR, Kite Pharmaceuticals, Anti-VEGFR2 CAR,  NIH, melanoma, non-small cell lung cancer, renal cell carcinoma, PD-1, PD-L1, CD274, B7-H1, PD-L2, CD273, B7-DC, PD-L4, CTLA4, B7.1, CD80, B7.2, CD86, repulsive guidance molecule b, RGMb

 

 

 

Latest News (December 4 2013):

In BOLT / MedPredict’s Psoriasis Thought Leader Panel #25 2013-12, seven of our experts (6 derms, 1 rheum; 4 US, 4 EU) in the treatment of moderate/severe psoriasis and moderate/severe psoriatic arthritis share their year-end views on the strengths and weaknesses of key competitors in development for these indications.

 

Psoriasis often appears between the ages of 15 and 25, but can develop at any age.  Psoriatic arthritis usually develops between the ages of 30 and 50.  Coupling these age of onset statistics with the experience that patients cycle through antipsoriatic therapy on average each 18-24 months, one realizes that there will be room for many new competitors in this space.

 

However, most of our thought leaders say that they will try two therapies from a class before moving on to a new mechanism of action.  This tempers the commercial opportunity for the 3rd, 4th and 5th competitor unless there is a significant benefit to the patient, physician or payer.

 

For the patient, there is a new paradigm: reaching PASI 100 is an attainable goal for more than 50% of patients with moderate / severe psoriasis (see IL17 inhibitors).  For the physician, “methotrexate without monitoring” offers a safe, easy to manage therapy (apremilast) for more moderate cases.  For payers, biosimilar versions of etanercept (in the EU) and adalimumab (worldwide) are imminent.

 

Against this backdrop our Panel talks about the most recent trial data for the following mechanisms of action and molecules:

 

TNF: adalimumab, etanercept, golimumab, certolizumab, ABP-501, PF-06410293, CT-P13, CHS-0214

IL23: ustekinumab, tildrakizumab, guselkumab, BI-655066

IL17: brodalumab, secukinumab, ixekizumab

IL17 / TNF: ABT-122

RORγt

JAK: tofacitinib, baricitinib, GSK2586184, INCB039110, ASP015k, PF-04965842, ABT494

PDE4: apremilast

IL6: clazakizumab

Fumarate: XP-23829, LAS-41008

Innate Immunity

 

(September 22, 2013):

Non-Small Cell Lung Cancer

BOLT / MedPredict NSCLC Thought Leader Panel #36, published September 2013, shares key insights gleaned from our Panel of experts in non-small cell lung cancer during interviews we conducted since ASCO 2013.  This report focuses on adenocarcinomas and squamous cell carcinomas of the lung.  There is little discussion of other lung cancers with partial or IHC adenocarcinoma differentiation (e.g. large cell carcinomas, small cell carcinomas or large cell endocrine carcinomas, brief comments on adenosquamous carcinomas in the section on the SQUIRE trial with necitumumab).  The report is generally organized by target mechanism.

More than a decade since EGFR was identified as a substantial driver for adenocarcinomas, and five years since the importance of ALK fusions was shown, the targets for treatment of this histology has matured.  We share our Panel’s opinions on next generation EGFR and ALK inhibitors, and newer targets: ROS, RET, HER2 and others.

In contrast, squamous cell carcinomas of the lung lack an approved targeted therapy.  While less mature, it looks like this will change shortly, as FGF1 inhibitors make their way through development.

The major story in the solid tumor world this year has been the explosive development in the area of checkpoint modulation. There is speculation that PD-1 and other checkpoint approaches will be most beneficial in the squamous NSCLCs.  The Panel reviews the safety and efficacy data presented on the PD-1 and PD-L1 inhibitors.

Finally, the Panel sheds light on PI3K in brain metastases, CDK4/6, HSP90 and other topics that will impact the changing landscape of NSCLC in the next few years.

Mechanisms / Drugs discussed in this report:

ALK, Xalkori, crizotinib, Pfizer, LDK378, Novartis, AP26113, Ariad, RO5424802, CH5424802, AF802, Chugai, Roche, ASP3026, Astellas,

AXL, BGB324, BerGenBio,

CDK4/6, LY2835219, Lilly,

CTLA4, Yervoy, ipilimumab, BMS,

DDR2, Sprycel, dasatinib, BMS,

EGFR, Tarceva, erlotinib,  Genentech, Astellas, necitumumab Lilly, CO-1686, Clovis, AP26113, Ariad, AZD9291, AstraZeneca,

EGFR/HER2, Gilotrif, afatinib, Boehringer-Ingelheim, dacomitinib, Pfizer,

FGF, BGJ398, Novartis, JNJ-42756493, Astex, Janssen, AZD-4547, AstraZeneca, Iclusig, ponatinib, Ariad, LY-2874455, Lilly, SSR128129E, Sanofi-Aventis,

Folate, Alimta, pemetrexed, Lilly, vintafolide, Merck, Endocyte,

HSP90, ganetespib, Synta, AUY922, Novartis, AT13387, Astex, retaspimycin, IPI-504, Infinity,

KRAS,

MEK, selumetinib, AstraZeneca, Array, MEK-162, Novartis, Array,

MET, onartuzumab, MetMAb, Genentech,

MUC1, Stimuvax, L-BLP25, Oncothyreon, Merck Serono,

PD-1, PD-L1, MPDL3280A, Genentech, lambrolizumab, MK-3475, Merck, nivolumab, BMS, Ono, ANB011, AnaptysBio,

PI3K, brain metastases,

PS, bavituximab, Peregrine,

Reovirus, Reolysin, pelareorep, Oncolytics,

RET Fusion, cabozantinib, Cometriq, Exelixis, Iclusig, ponatinib, Ariad,

ROS1, Xalkori, crizotinib, Pfizer,

Vaccine, MAGE-A3, GlaxoSmithKline, Agenus,

VEGF, Avastin, bevacizumab, Genentech, Vargatef, nintedanib, Boehringer-Ingelheim

 

 

 

 

 

Latest News (July, 2013):

We’re Closing Our Doors

Since BOLT’s first day of business in 1996, and MedPredict’s in 2006 we have been reachable to help our clients.  Last July 4th one of our clients tracked me down in Northern Idaho (yes, they have cell phone service.  Sort of) for an emergency project.  But this year, come the end of July, some of us are going to Sierra Prieta (google it) to dig latrines and not shower for a week.  We have this expression in our office: “That’s a 1st World problem”.  Even as we work to help patients receive and Pharma develop new therapies for hard to treat diseases, we are working on 1st World problems.  But “I have to carry water two miles this morning”, well, that’s definitely a 3rd World problem.  And we want to get out of the office, out of Snottsdale AZ, and live for a week like most people on Earth do.  It’s one thing to talk about solving the world’s problems; and sending money is pretty much just talk.  It’s another to go lay pipe.  So we’re going to dig ditches and lay pipe.  See you when we’re back and showered.

- jb

 

 

 

 

Looking to access BOLT’s Syndicated Thought Leader Panel reports? Over the past 15 years BOLT International has moderated over 4,000 Thought Leader interviews across a wide range of therapeutic categories.  These are summarized and analyzed in BOLT’s Thought Leader Panels; many of which are available to the public.  Contact me by email to discuss pricing (jeff@boltinternational.com).  We have recently installed a “buy now” feature on this website.  There you will see our most current releases, available for instant purchase by credit card.  If you don’t see what you want, ask.  A note to patients:  we discount our pricing (sometimes down to $0) to bona fide patients on a case-by-case basis – especially if our information will help you and your physician improve your care.  Seriously, we’ll need a note from your doctor!

Competence – BOLT International’s core competence is the integration of healthcare and pharmaceutical information sets into insightful commercial strategies. Our comprehensive understanding of healthcare product lifecycles – from biotech start-ups through research and clinical development, and onto global marketing, pricing and reimbursement strategies – permits us to develop concise, actionable recommendations.

Experience – BOLT’s leadership position in Healthcare Competitive Intelligence is derived from years of professional experience in both the science and the business of healthcare. BOLT’s principals know the industry, the firms, the markets, the politics and the technologies. This experience base – enhanced with BOLT’s THOUGHT LEADER physician panels, and our secondary information gathering and analysis techniques – permits us to provide actionable recommendations to a wide-variety of healthcare industry clients.

Knowledge – BOLT’s THOUGHT LEADER panels give us proprietary access to decision makers (physicians, patients, payers and regulators) in numerous geographies. This in turn drives our understanding of key issues and development of winning strategies – Strategies that reflect a complete analysis of the events predictive of both the direction and the rate of change within the healthcare industry. As a result, you’ll implement sound decisions with the confidence that your actions are based on the most comprehensive competitive, technical and financial analyses available.

Attention – BOLT provides the attention to service and detail that can be missing when dealing with large, general competitive intelligence firms. Our ability to meet your timing needs and to deliver the quality of analysis you demand is unparalleled.